LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 9/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $5 | $5 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $1 |
| Enterprise Value | $2 | $5 | $5 | $4 |
| Revenue | – | – | $0 | $0 |
| % Growth | – | – | -19.7% | – |
| Gross Profit | – | – | $0 | $0 |
| % Margin | – | – | 25.4% | 79.3% |
| EBITDA | – | – | -$0 | -$0 |
| % Margin | – | – | -61% | -42.9% |
| Net Income | – | – | -$0 | -$0 |
| % Margin | – | – | -133.9% | -46.1% |
| EPS Diluted | – | – | -1.81 | -0.85 |
| % Growth | – | – | -112.9% | – |
| Operating Cash Flow | – | – | $0 | $0 |
| Capital Expenditures | – | – | $0 | $0 |
| Free Cash Flow | – | – | $0 | $0 |